{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:56:56Z","timestamp":1790398616473,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-026-00784-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:40:42Z","timestamp":1773823242000},"page":"439-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypertension Treatment with Angiotensin Receptor Blockers and Other Antihypertensive Agents: A Real-World Registry from a High-Volume Specialized Center Over TwoDecades"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0635-4921","authenticated-orcid":false,"given":"Giuliano","family":"Tocci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nardoianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marco","family":"Dutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallo","family":"Giovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allegra","family":"Battistoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"12","key":"784_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"38","key":"784_CR2","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"9","key":"784_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959\u201368.","journal-title":"JAMA"},{"issue":"6","key":"784_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of Population-Based studies from 90 countries. Circulation. 2016;134(6):441\u201350.","journal-title":"Circulation"},{"issue":"10199","key":"784_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S0140-6736(19)30955-9","volume":"394","author":"P Geldsetzer","year":"2019","unstructured":"Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1\u00b71 million adults. Lancet. 2019;394(10199):652\u201362.","journal-title":"Lancet"},{"issue":"4","key":"784_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/jhh.2016.71","volume":"31","author":"G Tocci","year":"2017","unstructured":"Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258\u201362.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"784_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40292-016-0173-0","volume":"23","author":"G Tocci","year":"2016","unstructured":"Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in different Macro-Areas in italy: analysis of a large database by the general practice. High Blood Press Cardiovasc Prev. 2016;23(4):387\u201393.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"Suppl D","key":"784_CR8","doi-asserted-by":"publisher","first-page":"D66","DOI":"10.1093\/eurheartj\/suz058","volume":"21","author":"C Torlasco","year":"2019","unstructured":"Torlasco C, Faini A, Makil E, Bilo G, Pengo M, Beaney T, et al. Nation-wide hypertension screening in italy: data from May measurements month 2017-Europe. Eur Heart J Suppl. 2019;21(Suppl D):D66\u201370.","journal-title":"Eur Heart J Suppl"},{"key":"784_CR9","doi-asserted-by":"crossref","unstructured":"Del Pinto R, Desideri G, Ferri C, Agabiti Rosei E. Real-world antihypertensive treatment Patterns, treatment Adherence, and blood pressure control in the elderly: an Italian Awareness-raising campaign on hypertension by senior Italia FederAnziani, the Italian society of hypertension and the Italian federation of general practitioners. High Blood Press Cardiovasc Prev; 2021.","DOI":"10.1007\/s40292-021-00465-7"},{"key":"784_CR10","doi-asserted-by":"crossref","unstructured":"Del Pinto R, Agabiti Rosei C, Borghi C, Cipollini F, Cottone S, De Giorgi GA, et al. May measure month 2022 in italy: A focus on Fixed-dose Combination, therapeutic Adherence, and medical inertia in a nationwide survey. High Blood Press Cardiovasc Prev; 2024.","DOI":"10.1007\/s40292-024-00642-4"},{"issue":"35","key":"784_CR11","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1093\/eurheartj\/ehab899","volume":"43","author":"G Corrao","year":"2022","unstructured":"Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312\u201322.","journal-title":"Eur Heart J"},{"key":"784_CR12","doi-asserted-by":"crossref","unstructured":"Pathak A, Kreutz R, Boulestreau R, Weber M, Mancia G. Prime time for (im) precision medicine: from randomized clinical trials to Real-World evidence. Eur J Prev Cardiol. 2025. p. zwaf427","DOI":"10.1093\/eurjpc\/zwaf427"},{"issue":"1","key":"784_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40292-020-00359-0","volume":"27","author":"G Tocci","year":"2020","unstructured":"Tocci G, Presta V, Ferri C, Redon J, Volpe M. Blood pressure targets achievement according to 2018 ESC\/ESH guidelines in three European excellence centers for hypertension. High Blood Press Cardiovasc Prev. 2020;27(1):51\u20139.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"6","key":"784_CR14","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s11845-021-02870-2","volume":"191","author":"C Kennedy","year":"2022","unstructured":"Kennedy C, Ali O, Farnan R, Stinson J, Gabr A, Hall M, et al. Clinical characteristics of two groups commonly referred to an Irish hypertension service-patients with resistant hypertension and young adults with hypertension. Ir J Med Sci. 2022;191(6):2549\u201357.","journal-title":"Ir J Med Sci"},{"issue":"3","key":"784_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41371-021-00514-7","volume":"36","author":"C Kennedy","year":"2022","unstructured":"Kennedy C, Farnan R, Stinson J, Hall M, Hemeryck L, O\u2019Connor P, et al. Referrals to, and characteristics of patients attending a specialist hypertension clinic. J Hum Hypertens. 2022;36(3):315\u201324.","journal-title":"J Hum Hypertens"},{"key":"784_CR16","doi-asserted-by":"crossref","unstructured":"Collaboration S-OwgaECr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455\u201367.","DOI":"10.1093\/eurheartj\/ehab312"},{"issue":"25","key":"784_CR17","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"collaboration SwgaECr","year":"2021","unstructured":"Collaboration SwgaECr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J"},{"issue":"9596","key":"784_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"4","key":"784_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/0151642-200815040-00008","volume":"15","author":"G Parati","year":"2008","unstructured":"Parati G, Omboni S, Palatini P, Rizzoni D, Bilo G, Valentini M, et al. Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours. High Blood Press Cardiovasc Prev. 2008;15(4):283\u2013310.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"7","key":"784_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","volume":"39","author":"GS Stergiou","year":"2021","unstructured":"Stergiou GS, Palatini P, Parati G, O\u2019Brien E, Januszewicz A, Lurbe E, et al. 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293\u2013302.","journal-title":"J Hypertens"},{"issue":"19","key":"784_CR21","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection E","year":"2001","unstructured":"Expert Panel on Detection E. Treatment of high blood cholesterol in A. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486\u201397.","journal-title":"JAMA"},{"issue":"2","key":"784_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","volume":"75","author":"A Virdis","year":"2020","unstructured":"Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75(2):302\u20138.","journal-title":"Hypertension"},{"issue":"1","key":"784_CR23","first-page":"88","volume":"28","author":"L Ryden","year":"2007","unstructured":"Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J. 2007;28(1):88\u2013136.","journal-title":"Eur Heart J"},{"issue":"28","key":"784_CR24","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"S-DWGECR Collaboration","year":"2023","unstructured":"Collaboration S-DWGECR. SCORE2-Diabetes: 10-year cardiovascular risk Estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544\u201356.","journal-title":"Eur Heart J"},{"issue":"23","key":"784_CR25","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","volume":"29","author":"F Van de Werf","year":"2008","unstructured":"Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-Segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J. 2008;29(23):2909\u201345.","journal-title":"Eur Heart J"},{"issue":"13","key":"784_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","volume":"28","author":"JP Bassand","year":"2007","unstructured":"Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598\u2013660.","journal-title":"Eur Heart J"},{"issue":"20","key":"784_CR27","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1093\/eurheartj\/ehm355","volume":"28","author":"K Thygesen","year":"2007","unstructured":"Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007;28(20):2525\u201338.","journal-title":"Eur Heart J"},{"key":"784_CR28","doi-asserted-by":"crossref","unstructured":"Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37(6):1583\u2013633. Primary prevention of ischemic stroke: a guideline from the American Heart Association\/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council.","DOI":"10.1161\/01.STR.0000223048.70103.F1"},{"key":"784_CR29","doi-asserted-by":"crossref","unstructured":"Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, the American Heart Association\/American Stroke Association Stroke Council. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from ; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93.","DOI":"10.1161\/STROKEAHA.108.192218"},{"issue":"28","key":"784_CR30","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219.","journal-title":"Eur Heart J"},{"issue":"33","key":"784_CR31","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"4","key":"784_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/08037050500230227","volume":"14","author":"LM Ruilope","year":"2005","unstructured":"Ruilope LM, Rosei EA, Bakris GL, Mancia G, Poulter NR, Taddei S, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 2005;14(4):196\u2013209.","journal-title":"Blood Press"},{"issue":"4","key":"784_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40292-017-0239-7","volume":"24","author":"M Volpe","year":"2017","unstructured":"Volpe M, Tocci G, de la Sierra A, Kreutz R, Laurent S, Manolis AJ, et al. Personalised Single-Pill combination therapy in hypertensive patients: an update of a practical treatment platform. High Blood Press Cardiovasc Prev. 2017;24(4):463\u201372.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"2","key":"784_CR34","first-page":"137","volume":"21","author":"M Volpe","year":"2014","unstructured":"Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev. 2014;21(2):137\u201347.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"7","key":"784_CR35","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","volume":"32","author":"S Oparil","year":"2010","unstructured":"Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with Olmesartan medoxomil, amlodipine besylate, and Hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252\u201369.","journal-title":"Clin Ther"},{"issue":"6","key":"784_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1751-7176.2011.00437.x","volume":"13","author":"MR Weir","year":"2011","unstructured":"Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and Olmesartan medoxomil\u2009\u2009\u00b1\u2009\u2009hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011;13(6):404\u201312.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"784_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00044011-200929060-00002","volume":"29","author":"M Volpe","year":"2009","unstructured":"Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using Olmesartan medoxomil, amlodipine and Hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig. 2009;29(6):381\u201391.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"784_CR38","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1185\/03007995.2012.740632","volume":"28","author":"WA Hsueh","year":"2012","unstructured":"Hsueh WA, Shojaee A, Maa JF, Neutel JM. Efficacy of amlodipine\/olmesartan medoxomil\u2009\u2009\u00b1\u2009\u2009HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Curr Med Res Opin. 2012;28(11):1809\u201318.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"784_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12325-012-0030-z","volume":"29","author":"J Neutel","year":"2012","unstructured":"Neutel J, Shojaee A, Maa JF. Efficacy of amlodipine\/olmesartan\u2009\u2009\u00b1\u2009\u2009hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy. Adv Ther. 2012;29(6):508\u201323.","journal-title":"Adv Ther"},{"issue":"2","key":"784_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3810\/pgm.2013.03.2646","volume":"125","author":"MR Weir","year":"2013","unstructured":"Weir MR, Shojaee A, Maa JF. Efficacy of amlodipine\/olmesartan medoxomil\u2009\u2009\u00b1\u2009\u2009hydrochlorothiazide in patients aged\u2009\u2265\u200965 or <\u200965 years with uncontrolled hypertension on prior monotherapy. Postgrad Med. 2013;125(2):124\u201334.","journal-title":"Postgrad Med"},{"issue":"3","key":"784_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353.","journal-title":"N Engl J Med"},{"issue":"9386","key":"784_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, Investigators EtOrocewPiscAd. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782\u20138.","journal-title":"Lancet"},{"issue":"9215","key":"784_CR43","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of Losartan compared with Captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan heart failure survival study ELITE II. Lancet. 2000;355(9215):1582\u20137.","journal-title":"Lancet"},{"issue":"9335","key":"784_CR44","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J, Group OSCotOS. Effects of Losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist Losartan. Lancet. 2002;360(9335):752\u201360.","journal-title":"Lancet"},{"issue":"20","key":"784_CR45","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, K\u00f8ber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893\u2013906.","journal-title":"N Engl J Med"},{"issue":"15","key":"784_CR46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"key":"784_CR47","doi-asserted-by":"publisher","first-page":"d2234","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.","journal-title":"BMJ"},{"issue":"4","key":"784_CR48","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12602-023-10105-2","volume":"15","author":"NA Taslim","year":"2023","unstructured":"Taslim NA, Yusuf M, Ambari AM, Del Rosario Puling IM, Ibrahim FZ, Hardinsyah H, et al. Anti-Inflammatory, Antioxidant, metabolic and gut microbiota modulation activities of probiotic in cardiac remodeling condition: evidence from systematic study and Meta-Analysis of randomized controlled trials. Probiotics Antimicrob Proteins. 2023;15(4):1049\u201361.","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"1","key":"784_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41\u20136.","journal-title":"Am J Med"},{"issue":"10","key":"784_CR50","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1464-5491.2011.03341.x","volume":"28","author":"CL Blacklock","year":"2011","unstructured":"Blacklock CL, Hirst JA, Taylor KS, Stevens RJ, Roberts NW, Farmer AJ. Evidence for a dose effect of renin-angiotensin system Inhibition on progression of microalbuminuria in type 2 diabetes: a meta-analysis. Diabet Med. 2011;28(10):1182\u20137.","journal-title":"Diabet Med"},{"issue":"9489","key":"784_CR51","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus Atenolol adding Bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes Trial-Blood pressure Lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906.","journal-title":"Lancet"},{"issue":"23","key":"784_CR52","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, et al. Benazepril plus amlodipine or Hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"}],"container-title":["High Blood Pressure &amp; Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00784-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-026-00784-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00784-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:02:29Z","timestamp":1781974949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-026-00784-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s40292-026-00784-7","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.T. has received honoraria from Menarini Italia and Menarini International for acting as a speaker in national and international symposia. MV has received honoraria for speaker bureau or Advisory Board from Astra Zeneca, Menarini International, Neopharmed, Novartis, Servier and he is supported by a Grant of the Italian Ministry of Health (\u201cRicerca Corrente\u201d). Other authors have no conflict of interest to disclose to the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the local Ethical Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}